Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Bioventus Inc. reported Fourth Quarter 2023 results: revenue $135.4 million, net income net loss of $7.7 million, EPS ($0.10) loss per share.
- Period
- Fourth Quarter 2023
- Revenue
- $135.4 million
- Net income
- net loss of $7.7 million
- EPS
- ($0.10) loss per share
- Result
- reported results
Exact text from the filing
For the fourth quarter, worldwide revenue totaled $135.4 million, an increase of 7.6% compared to the prior year. On an organic* basis, revenue increased 14.3%, driven by more than 20% growth in Pain Treatments and Surgical Solutions. The Company also reported a fourth quarter net loss from continuing operations of $7.7 million, compared to net loss from continuing operations of $35.4 million in the prior-year period. Adjusted EBITDA* from continuing operations of $22.0 million advanced 28.1% from $17.2 million last year due to strong revenue growth and disciplined cost management. Loss per share of Class A common stock from continuing operations was $0.10 per share, compared to a loss of $0.40 per share last year.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Bioventus Inc. reported Full Year 2024 results: revenue $520 million to $535 million, EPS $0.12 to $0.20. Guidance initiated.
- Period
- Full Year 2024
- Revenue
- $520 million to $535 million
- EPS
- $0.12 to $0.20
- Guidance
- initiated
- Result
- guidance update
Exact text from the filing
Bioventus introduced its financial guidance for full-year 2024. The Company expects: • Net sales of $520 million to $535 million • Adjusted EBITDA* of $89 million to $94 million • Non-GAAP EPS* of $0.12 to $0.20
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Bioventus Inc. reported Full Year 2023 results: revenue $512.3 million, net income net loss of $121.2 million, EPS ($1.54) loss per share.
- Period
- Full Year 2023
- Revenue
- $512.3 million
- Net income
- net loss of $121.2 million
- EPS
- ($1.54) loss per share
- Result
- reported results
Exact text from the filing
Bioventus’ full-year 2023 worldwide revenue totaled $512.3 million, which was even compared to the prior year. On an organic* basis, revenue increased 3.6%, driven by 9.4% growth in Surgical Solutions. The Company also reported a full-year 2023 net loss from continuing operations of $121.2 million, compared to net loss from continuing operations of $144.7 million in the prior year. Adjusted EBITDA from continuing operations* of $88.9 million advanced 29.5% from $68.6 million last year due to disciplined cost management and savings from a corporate restructuring implemented at the beginning of the year. Loss per share of Class A common stock from continuing operations was $1.54 per share, compared to a loss of $1.70 per share last year.
View on SEC.gov